THRD vs. TBPH, TVTX, LRMR, ANNX, FULC, CDMO, OCS, MRSN, NGNE, and KALV
Should you be buying TF Financial stock or one of its competitors? The main competitors of TF Financial include Theravance Biopharma (TBPH), Travere Therapeutics (TVTX), Larimar Therapeutics (LRMR), Annexon (ANNX), Fulcrum Therapeutics (FULC), Avid Bioservices (CDMO), Oculis (OCS), Mersana Therapeutics (MRSN), Neurogene (NGNE), and KalVista Pharmaceuticals (KALV). These companies are all part of the "pharmaceutical preparations" industry.
Theravance Biopharma (NASDAQ:TBPH) and TF Financial (NASDAQ:THRD) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, community ranking, profitability, dividends, valuation, institutional ownership, analyst recommendations, earnings and risk.
TF Financial has lower revenue, but higher earnings than Theravance Biopharma. TF Financial is trading at a lower price-to-earnings ratio than Theravance Biopharma, indicating that it is currently the more affordable of the two stocks.
TF Financial has a net margin of 0.00% compared to TF Financial's net margin of -96.12%. Theravance Biopharma's return on equity of -6.22% beat TF Financial's return on equity.
Theravance Biopharma received 276 more outperform votes than TF Financial when rated by MarketBeat users. However, 66.67% of users gave TF Financial an outperform vote while only 63.38% of users gave Theravance Biopharma an outperform vote.
Theravance Biopharma currently has a consensus price target of $20.50, indicating a potential upside of 121.86%. TF Financial has a consensus price target of $7.00, indicating a potential downside of 33.08%. Given TF Financial's stronger consensus rating and higher possible upside, research analysts clearly believe Theravance Biopharma is more favorable than TF Financial.
99.1% of Theravance Biopharma shares are held by institutional investors. Comparatively, 94.0% of TF Financial shares are held by institutional investors. 6.9% of Theravance Biopharma shares are held by company insiders. Comparatively, 4.8% of TF Financial shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Theravance Biopharma has a beta of 0.36, meaning that its share price is 64% less volatile than the S&P 500. Comparatively, TF Financial has a beta of 3.53, meaning that its share price is 253% more volatile than the S&P 500.
In the previous week, TF Financial had 7 more articles in the media than Theravance Biopharma. MarketBeat recorded 8 mentions for TF Financial and 1 mentions for Theravance Biopharma. TF Financial's average media sentiment score of 0.13 beat Theravance Biopharma's score of 0.00 indicating that Theravance Biopharma is being referred to more favorably in the media.
Summary
Theravance Biopharma beats TF Financial on 9 of the 17 factors compared between the two stocks.
Get TF Financial News Delivered to You Automatically
Sign up to receive the latest news and ratings for THRD and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding THRD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
TF Financial Competitors List
Related Companies and Tools
